Raportul
Știri verificate despre finanțări, sedii centrale și leadership de la cele mai inovatoare companii din lume
26,344 rapoarte și mai multe
Microbiotica Raises £36M Series C for Oral Microbiome Medicines
Microbiotica announced the first close of a £36 million ($48 million) Series C led by British Business Bank to advance MB310 into Phase 2 clinical development in ulcerative colitis.
Basecamp Research Raises $140M Series C for AI-Designed Medicines
Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.
Cloverleaf Bio Raises $33M Seed Round for RNA Cancer Therapeutics
Cloverleaf Bio closed an oversubscribed $33 million seed round to advance engineered tRNA therapeutics for liver and colorectal cancers.
Enginprime Medical Raises $12M Series A for Percutaneous Heart Pump Devices
Enginprime Medical closed a $12M Series A led exclusively by Qiming Venture Partners to fund the China registration trial of its OpusOne percutaneous ventricular assist device.
Remepy Raises $36M Series A to Advance Hybrid Drug Pipeline
Remepy raised a $36 million Series A led by O.G. Venture Partners and M Ventures to expand its Hybrid Drug pipeline and fund Phase III development of Hybridopa for Parkinson’s disease.
Amplifica Raises $26M Series B for Injectable Hair Growth Therapies
Amplifica raised an oversubscribed $26 million Series B led by Tasso Partners to advance clinical development of its injectable hair-growth pipeline.
Beyang Raises Nearly $30M Series A for AI-Driven Drug Discovery
Beyang Therapeutics raised nearly $30 million in an oversubscribed Series A co-led by Legend Capital and Shanghai Healthcare Capital to advance its AI-driven drug discovery platform and pipeline.
Infinimmune Raises $75M Series A for Human-Derived Antibody Drugs
Infinimmune raised a $75 million Series A co-led by Regeneron Ventures and Playground Global to advance human-derived antibody programs in atopic dermatitis and inflammatory disease.
Expedition Therapeutics Raises $115M Series B for Oral DPP1 Inhibitor for COPD
Expedition Therapeutics raised an oversubscribed $115 million Series B led by General Atlantic to advance its DPP1 inhibitor EXPD-101 through Phase 2 clinical development in COPD.
Afișare 9 rapoarte • Pagina 1 • Categorie: all
Rămâneți înaintea pieței
Primiți perspective săptămânale în inbox. Fără spam, doar inteligență.